1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEBeclabuvirCat. No.: HY-12429CAS No.: 958002-33-0Synonyms: BMS-791325分式: CHNOS分量: 659.84作靶點: HCV; HCV Protease作通路: Anti-infection; Metabolic Enzyme/Protease儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性

2、數(shù)據(jù)體外實驗 DMSO : 30 mg/mL (45.47 mM)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.5155 mL 7.5776 mL 15.1552 mL5 mM 0.3031 mL 1.5155 mL 3.0310 mL10 mM 0.1516 mL 0.7578 mL 1.5155 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Beclabuvir

3、是HCV NS5B RNA-依賴性 RNA 聚合酶抑制劑，也可抑制 HCV基因型 1，2，4，5 表達的 NS5B 蛋活性，IC50 值均 28 nM。IC50 & Target IC50: 28 nM (NS5B protein)1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體外研究 Beclabuvir demonstrates additive or synergistic antiviral activity with pegIFN/RBV and in 2- or 3-drugcombinations with a range of

4、 DAAs, such as HCV NS3 protease inhibitors, NS5A inhibitors and/ornucleoside NS5B inhibitors 2.體內(nèi)研究 The combination of beclabuvir with asunaprevir and daclatasvir achieves very high rates of viral eradication(about 90%) in patients infected with HCV genotype 1, which is the most common genotype worl

5、dwide 1.戶使本產(chǎn)品發(fā)表的科研獻 J Gastroenterol. 2019 Jan 25.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21.2. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1.J Viral Hepat. 2015 Aug;22(8):658-64.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 400-820-3792